Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H H Parving

Showing results (281-290 of 306) with videos related to

Pageof 31
Sort By:
Diabetes|March 31, 1998
Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patientsJ A Fagerudd, L Tarnow, P Jacobsen, et al.
Diabetologia|July 4, 2012
Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up studyJ W M Nin, I Ferreira, C G Schalkwijk, et al.
Journal of Human Hypertension|March 27, 2015
Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)S Theilade, B Claggett, T W Hansen, et al.
Tissue Antigens|October 1, 1986
HLA associations in insulin-dependent diabetes: search for heterogeneity in different groups of patients from a homogeneous populationA Svejgaard, B K Jakobsen, P Platz, et al.
Diabetologia|May 19, 2010
Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trialF Persson, P Rossing, H Reinhard, et al.
Diabetologia|August 6, 2005
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyG Boner, M E Cooper, K McCarroll, et al.
American Journal of Nephrology|June 13, 2009
The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristicsH J Lambers Heerspink, R Agarwal, D W Coyne, et al.
Diabetologia|January 13, 2011
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan TrialsM Porta, J W Hainer, S-O Jansson, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 27, 2007
Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetesA M W Spijkerman, M-A Gall, L Tarnow, et al.
Ugeskrift for Laeger|October 17, 2001
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]H H Parving, B M Brenner, M E Cooper, et al.
Pageof 31

Showing results (281-290 of 306) with videos related to

Sort By:
Pageof 31
Diabetes|March 31, 1998
Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patientsJ A Fagerudd, L Tarnow, P Jacobsen, et al.
Diabetologia|July 4, 2012
Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up studyJ W M Nin, I Ferreira, C G Schalkwijk, et al.
Journal of Human Hypertension|March 27, 2015
Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)S Theilade, B Claggett, T W Hansen, et al.
Tissue Antigens|October 1, 1986
HLA associations in insulin-dependent diabetes: search for heterogeneity in different groups of patients from a homogeneous populationA Svejgaard, B K Jakobsen, P Platz, et al.
Diabetologia|May 19, 2010
Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trialF Persson, P Rossing, H Reinhard, et al.
Diabetologia|August 6, 2005
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyG Boner, M E Cooper, K McCarroll, et al.
American Journal of Nephrology|June 13, 2009
The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristicsH J Lambers Heerspink, R Agarwal, D W Coyne, et al.
Diabetologia|January 13, 2011
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan TrialsM Porta, J W Hainer, S-O Jansson, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 27, 2007
Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetesA M W Spijkerman, M-A Gall, L Tarnow, et al.
Ugeskrift for Laeger|October 17, 2001
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]H H Parving, B M Brenner, M E Cooper, et al.
Pageof 31